HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
HC Wainwright & Co.将Context Therapeutics升级为收购,宣布5美元的目标
HC Wainwright & Co. analyst Emily Bodnar upgrades Context Therapeutics (NASDAQ:CNTX) from Neutral to Buy and announces $5 price target.
HC Wainwright & Co. 分析师艾米丽·博德纳尔将Context Therapeutics(纳斯达克股票代码:CNTX)从中性上调至买入,并宣布了5美元的目标股价。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。